NCT02052726View on ClinicalTrials.gov

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

PHASE1CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

January 22, 2014

Primary Completion Date

May 2, 2015

Study Completion Date

May 5, 2015

Conditions
Clostridium Difficile
Interventions
BIOLOGICAL

C. difficile vaccine with adjuvant

C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.

BIOLOGICAL

Placebo

Placebo administered at Month 0, 1, and 3.

BIOLOGICAL

C. difficile vaccine with adjuvant

C. difficile vaccine with adjuvant administered at day 1, 8, 30.

BIOLOGICAL

placebo

Placebo administered at Day 1, 8, and 30.

Trial Locations (10)

22003

Clinical Alliance for Research and Education - Infectious Diseases, LLC (CARE-ID), Annandale

27518

PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary

27612

Carolina Phase I Research, LLC, Raleigh

66212

Vince & Associates Clinical Research, Inc., Overland Park

Vince & Associates Clinical Research, Overland Park

77081

Texas Center for Drug Development, Inc., Houston

M9W 4L6

Manna Research Inc., Toronto

H4N 3C5

Diex Research Montreal Inc, Montreal

G1W4R4

Clinique Medicale St-Louis (recherche) Inc., Québec

J1H 1Z1

Diex Research Sherbrooke Inc., Sherbrooke

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02052726 - A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine. | Biotech Hunter | Biotech Hunter